{
  "docId": "019de515-1bf5-75fc-a19f-ef7a3323e229",
  "docSlug": "a43786f91ea3b101a0e62521077ddab4",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 14 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Adagio Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 14,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 30,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/8",
  "deckHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229",
  "deckJsonHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json",
  "deckAnchorHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.106,
        "w": 0.209,
        "x": 0.694,
        "y": 0.864
      },
      "kind": "list",
      "text": "✓ Neutralizing in standardized in vitro assays\nX Not neutralizing in standardized in vitro assays\n- Data Not Available\nCurrent Circulating Variants",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9a88815-e83f-49cd-ba42-35fadbcf7531",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.036,
        "w": 0.547,
        "x": 0.045,
        "y": 0.935
      },
      "kind": "paragraph",
      "text": "As of January 2023, there are no authorized or approved COVID-19 mAbs on the market in the U.S.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "188d9a39-d640-47a1-b256-d0e480bde323",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.57,
        "x": 0.045,
        "y": 0.864
      },
      "kind": "source-note",
      "text": "Neutralization data from published studies or measured by Invivyd using public sequences. Data current as of March 3, 2023. VYD222 data generated by Labcorp-Monogram Biosciences using the pseudovirus PhenoSense® SARS-CoV-2 Neutralizing Antibody Assay.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63e03f22-7af9-4fdc-8238-4a704144f5dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.619,
        "w": 0.91,
        "x": 0.045,
        "y": 0.212
      },
      "kind": "table",
      "text": "VARIANT, SUBLINEAGE, VYD222, EVUSHELD®*, BEBTELOVIMAB*\nWT(D614G), WT(D614G), ✓, ✓, ✓\nDelta, B.1.617.2, ✓, ✓, ✓\nOmicron, BA.1, ✓, -, ✓\nBA.4/5, ✓, ✓, ✓\nBA.4.6, ✓, X, ✓\nBF.7, ✓, -, -\nBQ.1.1, ✓, X, X\nBA.2.75, ✓, -, ✓\nXBB.1, ✓, X, X\nXBB.1.5, ✓, X, X",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d679da82-a793-439a-b921-117f632c1968",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.087,
        "w": 0.73,
        "x": 0.045,
        "y": 0.086
      },
      "kind": "title",
      "text": "VYD222 DEMONSTRATED BROAD IN VITRO NEUTRALIZING ACTIVITY AGAINST VARIANTS OF CONCERN AND SUB-LINEAGES TESTED",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bed88882-fbad-4f11-9efe-7040693e55cb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 5,
      "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 5,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0",
      "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.",
      "position": 1,
      "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}